Introduction
Worldwide around 35 million people suffer from heterozygous familial hypercholesterolaemia (HeFH), a condition characterized by genetically determined life-long elevation of the level of plasma lowdensity lipoprotein cholesterol (LDL-C). 1 Patients with HeFH may also have an increased plasma level of another atherogenic lipoprotein, lipoprotein (a) [Lp(a)], 2 that is under separate multigenic control and transmitted as a co-dominant trait. 3 An Lp(a) particle consists of an LDL-like particle which contains cholesterol, and in which the apolipoprotein B-100 is linked by disulphide bridges to a unique plasminogen-like glycoprotein, known as apolipoprotein (a), whose domains have inflammatory, oxidative, thrombotic, and antifibrinolytic properties. 4 Lp(a) can also bind more potently than conventional LDL to the extracellular matrix in the arterial wall, and is therefore uniquely atherogenic. Accordingly, elevated Lp(a) is a potent independent risk factor for atherosclerotic cardiovascular diseases (ASCVD) and plays a major role at all stages of atherogenesis, from early endothelial dysfunction to plaque rupture. 5, 6 The association between Lp(a) and ASCVD is generally consistent across racial groups, and, accordingly similar in African Americans and Caucasians. 7 Lipoprotein (a) as a cardiovascular risk factor in heterozygous familial hypercholesterolaemia patients
For the evaluation of the risk of acute myocardial infarction (AMI), plasma Lp(a) concentrations cut-off 30 or 50 mg/dL have been derived from numerous epidemiological studies in the general population. 6 In a recent very large study of 1 320 581 individuals, 1 in 3
were reported to have both elevated Lp(a), defined as > 50 mg/dL, 16 However, PCSK9 inhibitors, which also increase hepatic LDL receptor activity, have an Lp(a)-lowering effect. 17 Then, in our view, it is likely that the reduction in Lp(a) with PCSK9 inhibitors, when compared with statins, is related to a more marked upregulation of functional hepatic LDL receptors that clear Lp(a) particles. 12 Importantly, however, irrespective of the mechanism involved in an elevation of plasma concentration of Lp(a) in HeFH, such elevation is frequent in these patients. 13 In a prospective cohort study of 46 200 individuals from the Copenhagen General Population Study, patients with a clinical diagnosis of either possible, probable, or definite HeFH and a combination of high plasma concentrations of both LDL-C and Lp(a) were at particularly high risk of premature coronary artery disease (CAD). 2 Thus, the hazard ratio for AMI was 5.3 (95% CI 3.6-7.6) for the HeFH patients with an elevated concentration of Lp(a) exceeding 50 mg/dL. Moreover, in a recent cohort study of molecularly defined population of HeFH patients, with or without previous ASCVD (the SAFEHEART study), the adjusted hazard ratio in multivariable analysis for incident ASCVD was 1.52 (95% CI 1.05 -2.21) for the HeFH patients with an elevated concentration of Lp(a) above 50 mg/dL. 18 Hence, measurement of Lp(a) may be used to risk-stratify patients with HeFH, pointing to the need for more intensive LDL-cholesterol lowering with non-statin agents. 19 Lp(a) also appears to act synergistically with high LDL-C as a causal risk factor for CAD. This was shown in a very recent prospective cohort study of 939 patients aged 18 to 55 years and who developed premature acute coronary syndrome (ACS). 20 Thus, in ACS patients with an Lp(a) concentration >50 mg/dL, the strength of the Lp(a) and LDL-C interaction was increased when the LDL-C concentration was > 3.5 mmol/L. Importantly, with an Lp(a) > 30 mg/dL the strength of the interaction of high Lp(a) and LDL-C was increased when the LDL-C concentration was > 4.5 mmol/L, as typically found in HeFH patients. On the other hand, if LDL-C concentrations are reduced to low levels ranging from 1.0 to 2.0 mmol/L in non-HeFH patients, like in the AIM-HIGH trial, Lp(a) can still contribute to residual ASCVD risk. 21 This finding accords with the notion that Lp(a) has a proatherogenic effect also independent of LDL-C. 6 In the Pro(a)-Life study, a subgroup analysis stratified by LDL-C concentration suggested that the reduction in major coronary events was specifically related to the effect of apheresis on Lp(a) concentration. 22 In CHD patients on long-term statin therapy and with Lp(a) > _50 mg/dL and LDL-C < _ 2.6 mmol/L, reduction in Lp(a) concentration with selective Lp(a) apheresis was associated with regression of both carotid and coronary atherosclerosis.
23,24
A caveat: measurement of lipoprotein (a)
Lp(a) concentrations are only infrequently measured in clinical practice, posing a major gap in the care of HeFH. Of note, measurement of Lp(a) needs to be well standardized and an isoform independent immune-assay needs to be used. 25 Measurement of LDL-C also includes the cholesterol content of Lp(a) [Lp(a)-C]. 26 Hence, highly elevated Lp(a) levels contribute significantly to measured LDL-C levels and can therefore erroneously lead to a phenotypic diagnosis of HeFH. 2 Moreover, elevated Lp(a) also masks the true reduction in LDL-C in response to statins, and to a lesser extent also to PCSK9 inhibitors, the relative contribution to the measured LDL-C of a given Lp(a)-C concentration being the higher the lower the achieved 'statin-resistant' LDL-C concentration. The precise correction factors for adjusting LDL-C in relation to high and changing levels of Lp(a) need to be further investigated.
Cholesterol lowering therapies and lipoprotein (a)
Hormonal therapy with thyroid hormones have been found to lower Lp(a) concentrations rather moderately, i.e. by about 20%, and the therapeutic role of thyromimetics, such as eprotirome, which lowers Lp(a) by about 20-40%, is still under investigation. 27, 28 Interestingly, the Cholesteryl Ester Transfer Protein (CETP) inhibitors have also been found to reduce Lp(a) levels by 20-40%, the mechanism of Lp(a) reduction with the CETP inhibitor anacetrapib being suppressed production of Lp(a). 29 Future analysis of data from the REVEAL outcomes study with anacetrapid hopefully will reveal whether the drug will meet its primary cardiovascular end points also regarding lowering of Lp(a). 30 There are two new drugs that interfere with the production of apoB-containing lipoproteins. Lomitapide, an inhibitor of microsomal triglyceride transfer protein, and mipomersen, an apoB-antisense drug, both are lowering Lp(a) levels within the range of 25-30%. [31] [32] [33] [34] [35] These drugs are, however, currently approved for the treatment of homozygous FH only. 27, 28 Nicotinic acid (niacin) not only effectively decreases LDL-C and triglycerides, and increases HDL-C, but also lowers Lp(a) concentration by about 20%, probably by interfering with its production. 21, 27 Unfortunately, however, niacin, which failed to reduce cardiovascular events in patients with pre-existing ASCVD on top of maximal LDLlowering therapy (HSP2-THRIVE trial), frequently gives rise to adverse effects and is not available in many countries anymore. 36 Its use could be considered in statin-treated HeFH patients having high Lp(a), but the treatment should be carefully monitored and potential benefits should be considered in the context of any adverse events.
Although the statins possess a strong LDL-C concentration lowering ability, their impact on Lp(a) metabolism appears to be neutral, with no definitive evidence that they lower or increase the plasma concentrations of this lipoprotein particle. 28 Importantly, then, subjects on statin therapy, but having excessively elevated serum Lp(a) concentrations, continue to have substantial residual risk of CAD. This was demonstrated in the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial in non-HeFH patients. In this trial, however, rosuvastatin which effectively reduced serum LDL-C to a mean concentration of 1.4 mmol/L, also resulted in a small but statistically significant positive shift in the overall distribution of Lp(a), a finding that requires further investigation. 38 The benefit of rosuvastatin was blunted in the high Lp(a) concentration group, implying that specific reduction in Lp(a) concentration had been required. [38] [39] [40] As a new therapeutic option, PCSK9 inhibition on top of high intensity statin treatment may be particularly suitable for the HeFH patients, since it lowers the concentrations of both LDL-C and Lp(a). 19 44 The continual exposure of the coronary artery wall to a high plasma concentration of LDL-C in HeFH, and the value of further therapeutic lowering LDL-C concentration can be gauged by quantifying the life-long burden of risk derived from the cumulative burden of LDL-C years. 45 The cumulative LDL-C years define the age-dependent exposure of the coronary arterial wall to LDL-C (years x mmol/L), and reflect the unique risk of CAD attributable to genetically increased concentration of LDL-C from birth. Since the plasma concentration of LDL-C is elevated already in cord blood of HeFH patients and the concentrations of Lp(a) reach to adult concentrations within the first five years of life, 46, 47 a potentially synergistic action of high LDL-C and high Lp(a) appears to start early in life, and so would also accelerate the early development of atherosclerosis. We applied the aforementioned concept of cumulative LDL-C burden (years x mmol/L) to the seminal data of Alonso et al. 13 They analysed the risk of various forms of ASCVD, including AMI, ischaemic stroke or transitory ischaemic attack, claudication, or abdominal aortic aneurysm in HeFH patients with an Lp(a) concentration above or below 50 mg/dL. They reported that the ASCVD-free survival time was significantly reduced in HeFH male and female patients with Lp(a) >50 mg/dL, when compared with their counterparts having Lp(a) <50 mg/dL (P < 0.0001). As illustrated in Figure 1 , 10% of the HeFH patients with Lp(a) concentration > 50 and < 50 mg/dL had developed ASCVD, on average, by the ages of 44 and 47 years, respectively. Correspondingly, 40% of such patients had developed ASCVD by the ages of 60 and 67 years, respectively. Thus, the Lp(a)-dependent risk of ASCVD increased with age, the age difference between the > 50 and < 50 mg/dL groups increasing from 3 years to 7 years, reflecting differing cumulative effects of different Lp(a) concentrations on the development of coronary atherosclerosis.
In the study of Alonso et al., 13 the average plasma LDL-C concentration among all HeFH patients was 5.0 mmol/L, from which it can be imputed that the cholesterol burden reached at any age was 5.0 mmol/L x age in years. Had the HeFH patients used more effective cholesterol-lowering treatment, such as a PCSK9 inhibitor on top of a high intensity statins, and had this dual regimen been commenced at the age of 20 years (decreasing LDL-C concentration to 1.0 mmol/L), then the decrease in the residual risk attributed by LDL-C might have compensated for the residual risk attributed to the high Lp(a) concentration. Nevertheless, this conclusion underestimates the effect of the statin-PCSK9 inhibitor combination, since it does not account the potential Lp(a)-related benefits of PCSK9 inhibitors referred to above. Firstly, both the synergistic risk related to a combination of high LDL-C and high Lp(a) and, 20 secondly, the independent risk related to high Lp(a) alone may be diminished by adding a PCSK9 inhibitor to the statin. Regarding a treatment goal for Lp(a), the following proposition merit consideration. In the general population, Lp(a) concentrations not exceeding the range of 30-50 mg/dL have been defined to be within 'normal' range. However, a target concentration within this 'normal' range seems not to be a reasonable goal in the HeFH-population, consisting of patients who are already at high risk of CAD. Accordingly, the threshold value of 50 mg/dL, such as recently used by Alonso et al. 13 may be too high. We consider that the treatment goal could be more stringent, i.e. below 30 mg/ dL, because the association of Lp(a) concentration with the risk of CAD is a continuous variable. 50, 51 Reaching such a stringent goal is at present not feasible for patients with an increased concentration (> 50 mg/dL) of Lp(a).
From the above argument, we depict the effects on LDL-C and Lp(a) of two treatment options in three hypothetical patients with HeFH (Figure 2) , all having the same starting LDL-C concentration of 5 mmol/L, but each with an elevated Lp(a) of different magnitude, one having 50, the second 100, and the third 150 mg/ dL. Importantly, all three combinations of LDL-C and Lp(a) cause a very high CVD risk, and, accordingly, in each case the goal of LDL-C concentration is < 1.8 mmol/L. 19 . 42, 52 Panel A shows the treatment responses of LDL-C and Lp(a) with a high potency statin alone, Panel B shows responses when a PCSK9 inhibitor is added to the statin. Of note, statin treatment alone, although resulting in a 50% lowering of the LDL-C concentration (to a value of 2.5 mmol/L) fails to lower it to the goal (< 1.8 mmol/L), and the concentrations of Lp(a) remain practically unchanged. This means that residual risks persist attributed to both high LDL-C and Lp(a). When a PCSK 9 inhibitor is combined with the statin, the concentration of LDL-C reaches the goal. However, although the PCSK9 inhibitor lowers concentrations of Lp(a) by 15-30%, 17 the goal (below 30 mg/dL) is not reached, and a residual risk attributed to an elevated Lp(a) concentration remains in all three patients. In Figure 2 , we did not illustrate an option of adding ezetimibe; however, ezetimibe treatment is unlikely to be efficient especially when LDL-C is just above 1.8 mmol/L and Lp(a) is elevated. 52 In summary, even with the optimal presentday combination therapy with a potent statin and a PCSK9 inhibitor, an unmet need still exists in HeFH patients having an elevation of Lp(a).
Encouraging data from recent trials show rapid, selective, and very potent reduction of plasma Lp Lipoprotein (a) life years as a metric of cumulative cholesterol exposure
We propose that the continual exposure of the coronary artery wall to a high plasma concentration of Lp(a) in HeFH, and the value of its therapeutic lowering can be gauged by quantifying the life-long burden of risk derived from the cumulative burden of Lp(a) years. Like the cumulative LDL-C years, cumulative Lp(a) years define the agedependent exposure of the coronary arterial wall to Lp(a) (years x mg/dL), and, regarding Lp(a), reflect the unique risk of CAD attributable to genetically increased concentration of Lp(a). In Figure 3 , the cumulative burden of Lp(a) life years is illustrated a subject having a 'normal' Lp(a) concentration of 30 mg/dL and the therapeutic effects of two apo(a) antisense oligonucleotides (ASOs) with different efficacies are shown. 52 The parent ASO which lowers Lp(a) concentration from 50 to 15 mg/dL (by 70%) is illustrated in a patient in whom this therapy is initiated at the age of 20. Moreover, the therapeutic effect of the modified more potent ASO which lowers Lp(a) concentration from 50 to 5 mg/dL (by 90%) is shown. The figure depicts that, when the treatment with the parent ASO or with the modified more potent ASO is initiated at the age of 20, the Lp(a) burden reaches values below those of the subject with the Lp(a) level of 30 mg/dL at the age of about 35 or 50 years, respectively. The risk prediction in HeFH employs Lp(a) as a discrete or binary variable. 8, 13, 37 In the SAFEHEART study, age was treated as a separate continuous variable and Lp(a) as a binary variable for practical reasons. 18 Also, the burden generated by the product of age and Lp(a) would have predicted ASCVD, given the independent effects of the two predictor variables on the outcome variable. The independent effect of Lp(a) is supported by the recent finding that a one standard deviation decrease in genetically lowered Lp(a) level is associated with a 30% lower risk of CHD. 51 We concede that the concept of Lp(a)-life years needs to be further established as a useful predictor of ASCVD.
Conclusions: future perspectives
Since the combination of life-long elevation of both LDL-C and Lp(a) is a risk not only for CAD but also other forms of ASCVD, it is reassuring to learn that, apart from CAD, at least in the general population, genetically lowered Lp(a) concentrations are associated with a lower risk of peripheral vascular disease, stroke, heart failure, and aortic stenosis. 50 Lp(a) concentrations partly explain this variability in such presentation of ASCVD. Unfortunately, however, some HeFH patients have exceptionally high concentration of serum Lp(a) (>100 mg/dL). Especially these patients, like any of the HeFH patients with Lp(a) values >50 mg/dL, are still waiting for effective and specific Lp(a) lowering therapies (Figures 2 and 3) . Treatment with the apo(a)
antisense oligonucleotides would be a tailor-made strategy when addressing this high-risk group of patients. Indeed, the recent results with these new biological agents provide fresh hope for high-risk HeFH patients with very high Lp(a) concentrations. 56 We have proposed and depicted approaches for addressing the gap based on current guidelines and potential outcomes of new trials. In closing, we stress the need to test their efficacy, acceptability and costeffectiveness in lowering Lp(a) and related risk of ASCVD particularly in patients with HeFH. New pharmacological strategies for familial hypercholesterolaemia
